441 related articles for article (PubMed ID: 31248849)
21. A review of stereotactic ablative radiotherapy for nonmetastatic renal cell carcinoma.
Zalay O; Mehra P; Pereira I; Malone J; Malone S
World J Urol; 2024 Jan; 42(1):52. PubMed ID: 38244135
[TBL] [Abstract][Full Text] [Related]
22. Commentary on "A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma." Siva S, Pham D, Gill S, Corcoran NM, Foroudi F. Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Victoria, Australia.: BJU Int 2012;110(11 Pt B):E737-43. doi: 10.1111/j.1464-410X.2012.11550.x. [Epub 2012 Oct 29].
Gottschalk A
Urol Oncol; 2014 Apr; 32(3):374-5. PubMed ID: 24679465
[TBL] [Abstract][Full Text] [Related]
23. A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma.
Correa RJM; Ahmad B; Warner A; Johnson C; MacKenzie MJ; Pautler SE; Bauman GS; Rodrigues GB; Louie AV
Radiat Oncol; 2018 Mar; 13(1):47. PubMed ID: 29558966
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial.
Siva S; Pham D; Kron T; Bressel M; Lam J; Tan TH; Chesson B; Shaw M; Chander S; Gill S; Brook NR; Lawrentschuk N; Murphy DG; Foroudi F
BJU Int; 2017 Nov; 120(5):623-630. PubMed ID: 28188682
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK.
Correa RJM; Louie AV; Staehler M; Warner A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Siva S
J Urol; 2019 Jun; 201(6):1097-1104. PubMed ID: 30741849
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma in Non-surgical Candidates: Initial Clinical Experience.
Chang JH; Cheung P; Erler D; Sonier M; Korol R; Chu W
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e109-14. PubMed ID: 27131756
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review.
Kothari G; Foroudi F; Gill S; Corcoran NM; Siva S
Acta Oncol; 2015 Feb; 54(2):148-57. PubMed ID: 25140860
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
29. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401
[TBL] [Abstract][Full Text] [Related]
30. Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review.
Chen H; Laba JM; Zayed S; Boldt RG; Palma DA; Louie AV
J Thorac Oncol; 2019 Aug; 14(8):1332-1342. PubMed ID: 31075543
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients.
Ma MW; Li HZ; Gao XS; Liu MZ; Yin H; Yang KW; Chen JY; Ren XY; Wang D
Curr Oncol; 2022 Oct; 29(10):7832-7841. PubMed ID: 36290896
[TBL] [Abstract][Full Text] [Related]
32. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.
Boda-Heggemann J; Dinter D; Weiss C; Frauenfeld A; Siebenlist K; Attenberger U; Ottstadt M; Schneider F; Hofheinz RD; Wenz F; Lohr F
Radiat Oncol; 2012 Jun; 7():92. PubMed ID: 22710033
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA
Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998
[TBL] [Abstract][Full Text] [Related]
34. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic ablative radiotherapy in T1-2N0M0 small cell lung cancer: A systematic review and meta-analysis.
Safavi AH; Mak DY; Boldt RG; Chen H; Louie AV
Lung Cancer; 2021 Oct; 160():179-186. PubMed ID: 34330566
[TBL] [Abstract][Full Text] [Related]
36. Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma.
Reynolds HM; Parameswaran BK; Finnegan ME; Roettger D; Lau E; Kron T; Shaw M; Chander S; Siva S
PLoS One; 2018; 13(8):e0202387. PubMed ID: 30114235
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
[TBL] [Abstract][Full Text] [Related]
38. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
39. Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS).
Siva S; Louie AV; Kotecha R; Barber MN; Ali M; Zhang Z; Guckenberger M; Kim MS; Scorsetti M; Tree AC; Slotman BJ; Sahgal A; Lo SS
Lancet Oncol; 2024 Jan; 25(1):e18-e28. PubMed ID: 38181809
[TBL] [Abstract][Full Text] [Related]
40. [Stereotactic body radiation therapy for primary kidney cancer].
Abancourt L; Le Guévelou J; Taillez A; Vu A; de Crevoisier R; Supiot S; Hennequin C; Chapet O; Blanchard P; Mirabel X; Lartigau É; Pasquier D
Cancer Radiother; 2023 Sep; 27(6-7):568-572. PubMed ID: 37543493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
